Surface structured liposomes for site specific delivery of an antiviral agent-indinavir

Journal of Drug Targeting

Volumn 19, Issue 4, 2011, Pages 258-269

  Dubey, Vaibhav ^a   Nahar, Manoj ^a   Mishra, Dinesh ^a   Mishra, Pradyumna ^b   Jain, N K ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b BHOPAL MEMORIAL HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

drug delivery; drug targeting; liposomes; Targeted drug delivery

Indexed keywords

BETA DEXTRO 1 THIOMANNOPYRANOSIDE; CHOLESTEROL; DIMYRISTOYL PHOSPHATIDYLETHANOLAMINE; DISTEROYL PHOSPHATIDYL CHOLINE; FLUORESCEIN ISOTHIOCYANATE; INDINAVIR; LIPOCORTIN 5; LIPOSOME; PROPIDIUM IODIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; FLOW CYTOMETRY; KIDNEY; LIVER; LUNG; LYMPH NODE; MACROPHAGE; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SPLEEN; TISSUE DISTRIBUTION;

ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; CELL LINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HALF-LIFE; INDINAVIR; LIPOSOMES; MACROPHAGES; MALE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 79953006284     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2010.499460     Document Type: Article

References (62)

1. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM. (2003). Terapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs, 63, 741-753. (Pubitemid 36428444)
2. Allen TM, Hansen CB, Stuart DD. (1998). Targeted sterically stabilized liposomal drug delivery. In: Lasic DD, Papahadjopoulos D, eds. Medical Applications of Liposomes (pp. 297-323). Amsterdam: Elsevier Science Publishers.
3. Amiji MM, Vyas TK, Shah L. (2006). Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Delv, 3, 613-628. (Pubitemid 44383489)
4. Andrews L, Friedland G. (2000) Progress in the HIV therapeutics and the challenges of adherence to antiretroviral therapy. Inf Dis Clin N Amer, 14, 1-26.
5. Ashton PR, Boyd SE, Brown CL, Nepogodiev SA, Meijer EW, Peerlings HWI, Stoddart JF. (1997). Synthesis of glycodendrimers by modifcation of poly (propylene imine) dendrimers. Chem Eur J, 3, 974-984. (Pubitemid 27268764)
6. Barratt G, Tenu JP, Yapo A, Petit JF. (1986). Preparation and characterisation of liposomes containing mannosylated phospholipids capable of targetting drugs to macrophages. Biochim Biophys Acta, 862, 153-164. (Pubitemid 17181078)
7. Choi SU, Bui T, Ho RJ. (2008). pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. J Pharm Sci, 97, 931-943. (Pubitemid 351293892)
8. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. (1999). Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS, 13, 473-478.
9. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. (2006). Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood, 108, 2827-2835.
10. Dubey V, Mishra D, Asthana A, Jain NK. (2006). Transdermal delivery of a pineal hormone: melatonin via elastic liposomes. Biomaterials, 27, 3491-3496.
11. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. (2007). Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release, 123, 148-154. (Pubitemid 47562141)
12. Dusserre N, Lessard C, Paquette N, Perron S, Poulin L, Tremblay M, Beauchamp D, Désormeaux A, Bergeron MG. (1995). Encapsulation of foscarnet in liposomes modifes drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics. AIDS, 9, 833-841.
13. Dutta T, Agashe HB, Garg M, Balakrishnan P, Balasubramanium P, Kabra M, Jain NK. (2007). Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target, 15, 89-98. (Pubitemid 47161336)
14. Dutta T, Jain NK. (2007). Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta, 1770, 681-686. (Pubitemid 46281473)
15. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT. (1993). Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature, 362, 359-362. (Pubitemid 23101311)
16. Fidler IJ, Brown NO, Hart IR. (1985). Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously. J Biol Response Mod, 4, 298-309. (Pubitemid 15062179)
17. Fry DW, White JC, Goldman ID. (1978). Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem, 90, 809-815. (Pubitemid 9087732)
18. Furniss BS, Hannaford AJ, Smith PWG, Tatchell AR. (1989). Textbook of Organic Chemistry (pp. 644-650). Patparganj, New Delhi, India: Pearson Education Ltd.,Indian Branch.
19. Garcon N, Gregoriadis G, Taylor M, Summerfeld J. (1988). Mannose-mediated targeted immunoadjuvant action of liposomes. Immunology, 64, 743-745.
20. Garg M, Asthana A, Agashe HB, Agrawal GP, Jain NK. (2006). Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics. J Pharm Pharmacol, 58, 605-616.
21. Garg M, Dutta T, Jain NK. (2007a). Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. Eur J Pharm Biopharm, 67, 76-85. (Pubitemid 46991319)
22. Garg M, Dutta T, Jain NK. (2007b). Stability study of stavudine-loaded O-palmitoyl-anchored carbohydrate-coated liposomes. AAPS Pharm Sci Tech, 8, Article 38.
23. Garg M, Garg BR, Jain S, Mishra P, Sharma RK, Mishra AK, Dutta T, Jain NK. (2008). Radiolabeling, pharmacoscintigraphic evaluation and antiretroviral efcacy of stavudine loaded 99mTc labeled galactosylated liposomes. Eur J Pharm Sci, 33, 271-281.
24. Garg M, Jain NK. (2006). Reduced hematopoietic toxicity, enhanced cellular uptake and altered pharmacokinetics of azidothymidine loaded galactosylated liposomes. J Drug Target, 14, 1-11.
25. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. (1986). Te role of mononuclear phagocytes in HTLV-III/LAV infection. Science, 233, 215-219.
26. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. (1995). Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta, 1239, 133-144.
27. Herman EH, Rahman A, Ferrans VJ, Vick JA, Schein PS. (1983). Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res, 43, 5427-5432. (Pubitemid 14230160)
28. Kaur CD, Nahar M, Jain NK. (2008). Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target, 16, 798-805.
29. Kawakami S, Wong J, Sato A, Hattori Y Yamashita F, Hashida M. (2000). Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice. Biochim Biophys Acta, 1524, 258-265.
30. Kirpotin D, Park JW, Hong K, Keller G, Benz C, Paphadjopoulos D. (1996). Binding and endocytosis of sterically stabilized anti-HER2 immunoliposomes by human breast cancer cells. Proc Am Assoc Cancer Res, 37, 3186.
31. Klibanov AL, Serbina N, Torchilin VP, Huang L. (1996). Attachment of ligands to liposomes via PEG spacer for prolonged liposome circulation and targeting. J Liposome Res, 6, 195-196.
32. Levy JA. (1993). Pathogenesis of human immunodefciency virus infection. Microbiol Rev, 57, 183-289. (Pubitemid 23078442)
33. Lin JH, Chiba M, Balani SK, Chen IW, Kwei GY, Vastag KJ, Nishime JA. (1996). Species diferences in the pharmacokinetics and metabolism of indinavir, a potent human immunodefciency virus protease inhibitor. Drug Metab Dispos, 24, 1111-1120. (Pubitemid 26346225)
34. Litzinger DC, Buiting AM, van Rooijen N, Huang L. (1994). Efect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta, 1190, 99-107. (Pubitemid 24066264)
35. Lopez-Berestein G, Bodey GP, Frankel LS, Mehta K. (1987). Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol, 5, 310-317. (Pubitemid 17021617)
36. Lopez-Berestein G, Kasi L, Rosenblum MG, Haynie T, Jahns M, Glenn H, Mehta R, Mavligit GM, Hersh EM. (1984). Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res, 44, 375-378. (Pubitemid 14177766)
37. Mehta RT, Hopfer RL, McQueen T, Juliano RL, Lopez-Berestein G (1987). Toxicity and therapeutic efects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother, 31, 1901-1903. (Pubitemid 18009558)
38. Mishra D, Mishra PK, Dubey V, Nahar M, Dabadghao S, Jain NK. (2008). Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modifed liposomes. Eur J Pharm Sci, 33, 424-433.
39. Muller CD, Schuber F. (1989). Neo-mannosylated liposomes: synthesis and interaction with mouse Kupfer cells and resident peritoneal macrophages. Biochim Biophys Acta, 986, 97-105. (Pubitemid 19281628)
40. Nahar M, Dubey V, Mishra D, Mishra PK, Dube A, Jain NK. (2010). In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. J Drug Target, 18, 93-105.
41. Nicholson JK, Cross GD, Callaway CS, McDougal JS. (1986). In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). J Immunol, 137, 323-329. (Pubitemid 16100307)
42. Perez-Soler R. (1989). Liposomes as carriers of antitumor agents towards a clinical reality. Can Treat Rev, 16, 67-82. (Pubitemid 19225851)
43. Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ. (1982). Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res, 42, 1412-1422. (Pubitemid 12148785)
44. Rahman A, White G, More N, Schein PS. (1985). Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. Cancer Res, 45, 796-803. (Pubitemid 15161082)
45. Reiter WJ, Schön-Pernerstorfer H, Dorfnger K, Hofbauer J, Marberger M. (1999). Frequency of urolithiasis in individuals seropositive for human immunodefciency virus treated with indinavir is higher than previously assumed. J Urol, 161, 1082-1084. (Pubitemid 29426090)
46. Salahuddin S, Kok DJ, Buchholz NN. (2007). Infuence of body temperature on indinavir crystallization under loop of Henle conditions. J Antimicrob Chemother, 59, 114-117. (Pubitemid 46017911)
47. Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M. (2007). Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials, 28, 1434-1442. (Pubitemid 44959042)
48. Sato T, Sunamoto J. (1992). Recent aspects in the use of liposomes in biotechnology and medicine. Prog Lipid Res, 31, 345-372.
49. Schifman SS, Zervakis J, Hefron S, Heald AE. (1999). Efect of protease inhibitors on the sense of taste. Nutrition, 15, 767-772. (Pubitemid 29461023)
50. Senior JH. (1987). Fate and behaviour of liposomes in vivo: a review of controlling factors. Crit Rev Ter Drug Car Systems, 3, 123-193. (Pubitemid 17219201)
51. Shigeta K, Kawakami S, Higuchi Y, Okuda T, Yagi H, Yamashita F, Hashida M. (2007). Novel histidine-conjugated galactosylated cationic liposomes for efcient hepatocyte-selective gene transfer in human hepatoma HepG2 cells. J Control Release, 118, 262-270. (Pubitemid 46329736)
52. Singh P, Premkumar L, Mehrotra R, Kandpal HC, Bakhshi AK. (2008). Evaluation of thermal stability of indinavir sulphate using difuse refectance infrared spectroscopy. J Pharm Biomed Anal, 47, 248-254.
53. Sorensen EN, Weisman G, Vidaver GA. (1977). A sephadex column procedure for measuring uptake and loss of low molecular weight solutes from small, lipid-rich vesicles. Anal Biochem, 82, 376-384. (Pubitemid 8194188)
54. Toteva MM, Zanon R, Ostovic D. (2007). Kinetics and mechanism of the hydrolytic degradation of indinavir. Intramolecular catalysis. J Pharm Sci, 97, 3810-3819.
55. Treat J, Greenspan AR, Rahman A. (1989). Liposome-encapsulated doxorubicin: preliminary results of phase I and phase II trials. In: Lopez-Berestein G, Fidler IJ, eds. Liposomes in the Terapy of Infectious Diseases and Cancer (pp. 353-365). New York: Alan R.
56. Liss, Inc Verman Robert B. (1972). Te macrophage. In: Harrison RJ, Meminn RMH, ed. Biologocal Structure and Function (pp. 27-43). Vol II. London: Cambridge University Press.
57. Vlahakis SR, Villaisis-Keever A, Gomez T, Bren GD, Paya CV (2003). Human immunodefciency virus induced apaptosis of human hepatocytes via CXCR4. J Infect Dise, 188, 1455-1460. (Pubitemid 37523930)
58. von Briesen H, Andreesen R, Esser R, Brugger W, Meichsner C, Becker K, Rübsamen-Waigmann H. (1990). Infection of monocytes/macrophages by HIV in vitro. Res Virol, 141, 225-231. (Pubitemid 20147090)
59. Weiss RA. (1993). How does HIV cause AIDS? Science, 260, 1273-1279. (Pubitemid 23231970)
60. Williams GC, Sinko PJ. (1999). Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev, 39, 211-238. (Pubitemid 29430237)
61. Yamashita C, Sone S, Ogura T, Kiwada H. (1991). Potential value of cetylmannoside modifed liposomes as carriers of macrophage activators to human blood monocytes. Japan J Cancer Res, 82, 569-575.
62. Zalipsky S, Puntambekar B, Bolikas P, Engbers CM, Woodle MC. (1995). Peptide attachment to extremities of liposomal surface grafted PEG chains: preparation OF the long-circulating form of laminin pentapetide, YIGSR. Bioconj Chem, 6, 705-708.